HHS to study contract pharmacies for evidence of drug diversion.
Executive Summary
HHS TO STUDY CONTRACT PHARMACY DRUG DIVERSION in response to manufacturer concerns regarding the "potential for drug diversion," the agency announced in an Aug. 23 final notice of its guidelines on contract pharmacy services for public purchasers receiving federal drug discounts under Sec. 340B of the Public Health Services Act. However, HHS said it "has received no evidence of diversion that has required an official departmental investigation."